A Nasal Spray for Relief of Nasal Congestion in Infants and Toddlers With Common Cold

Inclusion Criteria: 1. Male and female infants and toddlers. 2. Aged 3 - 48 months (inclusive) at enrolment (Day 0). 3. Parent/legal guardian answering "yes" to the question "Do you feel that your child has a cold?" at enrolment. 4. Subjects with symptoms started not later than 48 hours prior to enrolment (Day 0). 5. Subjects with nasal congestion (blocked / stuffy nose) rated as at least score of 2 (moderately bothersome) on a 0 to 3-point scale, based on morning evaluation (within an hour of child awakening). 6. Subjects showing at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough. 7. Parent/legal guardian of the subject has given freely and expressly her/his informed consent. 8. Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected. Exclusion Criteria: 1. Subjects presenting an oral temperature greater than 38°C at enrolment (Day 0). 2. Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, etc.) at enrolment (Day 0). 3. Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at inclusion. 4. Subjects with a history of allergic rhinitis 5. Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g. asthma, pneumonia, laryngotracheobronchitis, sinusitis, etc). 6. Subjects presenting any kind of immunodeficiency. 7. Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products or of the rescue medication (paracetamol) 8. Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0). 9. Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study. 10. Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0). 11. Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing ≥ 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening 12. Subject who was abroad in a country with a higher incidence rate of Covid-19 than Poland, within 14 days before the beginning of the study. 13. Subject who have had contact with any person infected with COVID-19 within 10 days before the beginning of the study. 14. Subject who are currently home quarantined, as recommended by the Sanitary Inspection.